Biologic Therapy for the Treatment of Giant Cell Arteritis

Successful Antiviral Treatment of Giant Cell Arteritis and Takayasu Arteritis.

Author Affiliations:Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montréal, Quebec, Canada (Bourassa, Dion, Rouleau); Group for AdvancedMolecular Investigation, Graduate Program in Health Sciences, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil (Raskin); Genetika–Centro de Aconselhamento e Laboratório de G...

Heparin therapy in giant cell arteritis.

The diagnosis and treatment of giant cell arteritis.

BACKGROUND Giant cell arteritis (GCA) is the most common systemic vasculitis in persons aged 50 and above (incidence, 3.5 per 100,000 per year). It affects cranial arteries, the aorta, and arteries elsewhere in the body, e.g., in the limbs. METHODS We selectively review the pertinent literature, including guidelines and recommendations from Germany and abroad. RESULTS The typical symptoms o...

Giant cell arteritis

Giant cell arteritis (GCA), temporal arteritis or Horton’s arteritis, is a systemic vasculitis which involves large and medium sized vessels, especially the extracranial branches of the carotid arteries, in persons usually older than 50 years. Permanent visual loss, ischaemic strokes, and thoracic and abdominal aortic aneurysms are feared complications of GCA. The treatment consists of high dos...

Giant cell arteritis.

Permanent, severe loss of vision is a feared complication; however, it is not the sole possible devastating outcome of giant cell arteritis. Myocardial infarction, ischemic stroke and limb gangrene may also occur. Thor acic aortic aneurysms are seen over 17 times more often in patients with giant cell arteritis than in age-matched controls. The optimal work-up includes erythrocyte sedimentation...